BioCentury | May 11, 2017
Translation in Brief

Going universal

...can be used off-the-shelf to kill a wide range of solid and hematological cancers. Formerly Cardio3 BioSciences S.A....
BioCentury | Jun 20, 2015
Financial News

Celyad shares fall after U.S. listing

...therapy based on autologous stem cells diferrentiated into cardiac precursors called cardiopoetic cells. Celyad, formerly Cardio3 BioSciences S.A....
BioCentury | May 4, 2015
Clinical News

CAR-NKG2D: Phase I started

...receive doses comprising 1x10 6, 3x10 6, 1x10 7 and 3x10 7 CAR-NKG2D T cells. Cardio3 BioSciences S.A....
BioCentury | Apr 13, 2015
Clinical News

C-Cure: Phase III ongoing

...of futility and indicated that there are no major or unexpected safety concerns with C-Cure. Cardio3 BioSciences...
BioCentury | Apr 6, 2015
Financial News

Cardio3 BioSciences proposes follow-on

Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Business: Cardiovascular Date announced: 2015-04-01 Type: Follow-on To be raised: TBD Shares: TBD Price prior: EUR43.95 Note: Cardio3 proposed a public offering in the U.S. WIR Staff...
BioCentury | Mar 2, 2015
Financial News

Cardio3 BioSciences S.A completes private placement

Cardio3 BioSciences S.A . (Euronext:CARD), Mont-Saint-Guibert, Belgium Business: Cardiovascular Date completed: 2015-02-27 Type: Private placement Raised: EUR31.8 million ($36 million) Shares: 713,380 Price: EUR44.50 Shares after offering: 7.8 million Placement agents: UBS; Bryan, Garnier; Petercam Investor:...
BioCentury | Feb 28, 2015
Financial News

Cardio3 raises EUR 31.7M

Cardio3 BioSciences S.A. (Euronext:CARD) raised EUR 31.7 million ($36 million) through the sale of 713,380 shares at EUR 44.50 in a private placement with undisclosed institutional investors in the U.S. and Europe. UBS was the...
BioCentury | Jan 5, 2015
Clinical News

C-Cure: Completed Phase III enrollment

...Phase III CHART-1 trial evaluating a catheter injection of C-Cure in =240 advanced CHF patients. Cardio3 BioSciences S.A....
BioCentury | Dec 15, 2014
Clinical News

C-Cure: Phase III start

...international Phase III CHART-2 trial to evaluate C-Cure comprising 600 million cells in =240 patients. Cardio3 BioSciences S.A....
BioCentury | Dec 15, 2014
Company News

CorQuest Medical, Cardio3 BioSciences deal

...year end 2016. Cardio3 declined to disclose financial terms. CorQuest Medical Inc. , Miami, Fla. Cardio3 BioSciences S.A....
Items per page:
1 - 10 of 51
BioCentury | May 11, 2017
Translation in Brief

Going universal

...can be used off-the-shelf to kill a wide range of solid and hematological cancers. Formerly Cardio3 BioSciences S.A....
BioCentury | Jun 20, 2015
Financial News

Celyad shares fall after U.S. listing

...therapy based on autologous stem cells diferrentiated into cardiac precursors called cardiopoetic cells. Celyad, formerly Cardio3 BioSciences S.A....
BioCentury | May 4, 2015
Clinical News

CAR-NKG2D: Phase I started

...receive doses comprising 1x10 6, 3x10 6, 1x10 7 and 3x10 7 CAR-NKG2D T cells. Cardio3 BioSciences S.A....
BioCentury | Apr 13, 2015
Clinical News

C-Cure: Phase III ongoing

...of futility and indicated that there are no major or unexpected safety concerns with C-Cure. Cardio3 BioSciences...
BioCentury | Apr 6, 2015
Financial News

Cardio3 BioSciences proposes follow-on

Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Business: Cardiovascular Date announced: 2015-04-01 Type: Follow-on To be raised: TBD Shares: TBD Price prior: EUR43.95 Note: Cardio3 proposed a public offering in the U.S. WIR Staff...
BioCentury | Mar 2, 2015
Financial News

Cardio3 BioSciences S.A completes private placement

Cardio3 BioSciences S.A . (Euronext:CARD), Mont-Saint-Guibert, Belgium Business: Cardiovascular Date completed: 2015-02-27 Type: Private placement Raised: EUR31.8 million ($36 million) Shares: 713,380 Price: EUR44.50 Shares after offering: 7.8 million Placement agents: UBS; Bryan, Garnier; Petercam Investor:...
BioCentury | Feb 28, 2015
Financial News

Cardio3 raises EUR 31.7M

Cardio3 BioSciences S.A. (Euronext:CARD) raised EUR 31.7 million ($36 million) through the sale of 713,380 shares at EUR 44.50 in a private placement with undisclosed institutional investors in the U.S. and Europe. UBS was the...
BioCentury | Jan 5, 2015
Clinical News

C-Cure: Completed Phase III enrollment

...Phase III CHART-1 trial evaluating a catheter injection of C-Cure in =240 advanced CHF patients. Cardio3 BioSciences S.A....
BioCentury | Dec 15, 2014
Clinical News

C-Cure: Phase III start

...international Phase III CHART-2 trial to evaluate C-Cure comprising 600 million cells in =240 patients. Cardio3 BioSciences S.A....
BioCentury | Dec 15, 2014
Company News

CorQuest Medical, Cardio3 BioSciences deal

...year end 2016. Cardio3 declined to disclose financial terms. CorQuest Medical Inc. , Miami, Fla. Cardio3 BioSciences S.A....
Items per page:
1 - 10 of 51